Maetzold Derek J's Form 4 filing
Castle Biosciences IncCSTL · filed Nov 4, 2026
- Accession no.
- 0001628280-26-070131
- Filed
- Nov 4, 2026, 4:07 PM ET
- Trade date
- Nov 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions. Open-market sales total $523.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | SSaleDisposed | −7,555 | $36.01F2 | −$272,017.78 | 4,929 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −2,816 | $36.01F2 | −$101,390.08 | 2,024 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −2,393 | $36.01F2 | −$86,159.97 | 1,721 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −1,025 | $36.81F5 | −$37,734.35 | 3,904 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −382 | $36.81F5 | −$14,062.95 | 1,642 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −325 | $36.81F5 | −$11,964.55 | 1,396 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $35.610 to $36.593, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $36.610 to $37.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.